Adamas Pharmaceuticals, Inc. ADMS

Adamas Pharmaceuticals, Inc. Revenue 2011-2026 | ADMS

Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.

Traditionally defined as follows:
Revenue = Price * Quantity of products

Revenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.^[1]

This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.

Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.

Annual Revenue Adamas Pharmaceuticals, Inc.

2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
74.5 M	54.6 M	34 M	571 K	572 K	1.92 M	55.8 M	71.1 M	37.5 M	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
74.5 M	571 K	36.7 M

References

Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).

Revenue of other stocks in the Biotechnology industry

Issuer	Revenue	Price	% 24h	Market Cap	Country
MorphoSys AG MOR	238 M	-	2.43 %	$ 254 M	Germany
I-Mab IMAB	88 M	-	-	$ 866 M	China
Alexion Pharmaceuticals, Inc. ALXN	6.07 B	-	-	$ 40.3 B	USA
Genfit SA GNFT	70.9 M	-	2.54 %	$ 160 B	France
Midatech Pharma plc MTP	381 K	-	-18.52 %	$ 27.3 M	Britain
EyeGate Pharmaceuticals, Inc. EYEG	12.1 K	-	-1.52 %	$ 24.7 M	USA
Acorda Therapeutics ACOR	118 M	-	-24.86 %	$ 820 K	USA
Adverum Biotechnologies ADVM	1 M	-	-	$ 86.2 M	USA
Advaxis ADXS	13 K	-	-9.65 %	$ 45.9 M	USA
Aeterna Zentaris AEZS	9.59 M	-	5.93 %	$ 314 M	Canada
AgeX Therapeutics AGE	130 K	-	-10.17 %	$ 12.2 K	USA
AIkido Pharma AIKI	123 M	-	1.93 %	$ 17.4 M	USA
Aeglea BioTherapeutics AGLE	886 K	-	-	$ 1.01 B	USA
Applied Genetic Technologies Corporation AGTC	325 K	-	-	$ 26.5 M	USA
Институт стволовых клеток человека ISKJ	1.08 B	-	-	-	Russia
Alpine Immune Sciences ALPN	30.1 M	-	-	$ 2.17 B	USA
Aravive ARAV	9.14 M	-	-13.39 %	$ 1.45 M	USA
Aptinyx APTX	1 M	-	-39.0 %	$ 4.57 M	USA
CureVac N.V. CVAC	48.9 M	-	-	$ 867 M	Germany
AstraZeneca PLC AZN	58.7 B	-	-	$ 96.9 B	Britain
Avenue Therapeutics ATXI	1.4 M	-	-52.27 %	$ 4.45 M	USA
Ayala Pharmaceuticals AYLA	692 K	-	-	$ 7.46 M	Israel
BeiGene, Ltd. BGNE	5.34 B	-	0.49 %	$ 251 B	Cayman-islands
bluebird bio BLUE	29.5 M	-	-	$ 546 M	USA
Brickell Biotech BBI	8.01 M	-	-5.38 %	$ 6.06 M	USA
CASI Pharmaceuticals CASI	30.2 M	-	-	$ 35.4 M	USA
Ampio Pharmaceuticals AMPE	1.16 M	-	-11.43 %	$ 502 K	USA
ChemoCentryx CCXI	32.2 M	-	-	$ 3.74 B	USA
AlloVir ALVR	165 K	-	4.14 %	$ 49.1 M	USA
Завод ДИОД DIOD	517 M	-	-	-	Russia
Фармсинтез LIFE	372 M	-	-	-	Russia
Chimerix CMRX	324 K	-	-	$ 756 M	USA
Teligent, Inc. TLGT	45.3 M	-	-13.85 %	$ 16.1 M	USA
AbbVie ABBV	16.6 B	$ 208.7	-0.07 %	$ 369 B	USA
Calithera Biosciences CALA	9.75 M	-	-10.95 %	$ 876 K	USA
Cara Therapeutics CARA	21 M	-	-3.03 %	$ 260 M	USA
Viela Bio, Inc. VIE	11.7 M	-	-	$ 2.91 B	USA
AbCellera Biologics ABCL	75.1 M	$ 3.52	-0.14 %	$ 1.05 B	Canada